Well you started it

[Guest guest]

Sexuality and Cancer (Sometimes, unlike the nausea, hair loss, fatigue, and

other side effects of cancer treatment, sexual problems don't resolve when the

treatment ends. However, in many cases they do. It's important to know and

understand that sexual dysfunction, diminished libido, and decreased intimacy

often have multiple causes and characteristics.) See tje website for more

information.

http://www.caring4cancer.com/go/cancer/wellbeing/physical-wellbeing/sexuality-an\

d-cancer.htm

____________________________________________

U.S. FDA cautions consumers against cancer 'cures'

WASHINGTON (Reuters) - Consumers should beware of products sold on the Internet

that claim to cure cancer, U.S. health officials said on Tuesday, threatening

penalties against more than two dozen companies selling creams, tea and pills as

treatments for the disease.

___________________________________________

a.. June 6, 2008

Cancer warning added to diabetic foot gel

WASHINGTON (Reuters) - & has added a strong " black box " warning

about the risk of dying from cancer to the prescribing instructions for the

company's Regranex diabetic foot gel, U.S. regulators said on Friday.

a.. ____________________________________

Other tyrosine kinase inhibitors - There are many including SKI606, INNO406,

and others. Trials with these drugs are available and you may wish to ask your

doctor about whether you may benefit from them.

Other targeted therapies - A class of drugs called aurora kinase inhibitors may

also be active in CML, particularly in patients with one particular resistant

mutation to the above drugs—called T315I. These include drugs like MK0457,

AT9283, KW2449, and others.

Other programs - The combination of cytarabine and interferon is a reasonable

treatment option for patients unable to pursue imatinib or curative treatment

with allogeneic stem cell transplantation.

A drug called homoharringtonine is designed to reduce the number of leukemia

cells. Patients who received homoharringtonine experienced a higher complete

hematologic remission rate and a higher cytogenetic remission rate

(disappearance of the Philadelphia chromosome) compared with patients who only

received interferon. The patients in the homoharringtonine group also needed

less interferon to stay in remission. Current and future studies will address

the best way to combine this and other drugs like imatinib.

Fluorescence in situ hybridization (FISH), detects the Philadelphia chromosome

in the blood, rather than the bone marrow, of people with CML who had undergone

treatment. The FISH test was as sensitive as bone marrow aspiration in detecting

the Philadelphia chromosome in the blood and helping to determine the treatment

outcomes for these patients.

The FISH test may be used to determine the treatment outcomes for individuals

with CML without use of a bone marrow examination. However, the FISH test may

not be used exclusively; those who test negative for the Philadelphia chromosome

will need a follow-up with a more sensitive test—called a polymerase chain

reaction (PCR). The FISH test appears to be an improved method for the routine

monitoring of treatment outcomes in people with CML. You may wish to talk with

your doctor about the advantages and disadvantages of FISH and PCR testing and

other blood tests in determining the effectiveness of your treatment.This

content was last modified on August 11, 2007.

http://www.caring4cancer.com/go/cml/treatments/strategies-to-improve-treatment.h\

tm

Blessings,

Lottie